Trousseau’s syndrome – what is the evidence?

Mats Ögren; David Bergqvist; Karin Wåhlander; Henry Eriksson; Nils H. Sternby

doi:10.1160/TH05-10-0694

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2006; 95(03): 541-545
DOI: 10.1160/TH05-10-0694

Cellular Proteolysis and Oncology

Schattauer GmbH

Trousseau’s syndrome – what is the evidence?

A population-based autopsy study

Authors

Mats Ögren

¹Department of Vascular Surgery, Uppsala University Hospital, Uppsala
David Bergqvist

¹Department of Vascular Surgery, Uppsala University Hospital, Uppsala
Karin Wåhlander

²Department of Medicine, Sahlgrenska University Hospital/Östra, Göteborg
Henry Eriksson

²Department of Medicine, Sahlgrenska University Hospital/Östra, Göteborg
Nils H. Sternby

³Department of Pathology, Lund University, Malmö University Hospital, Malmö; Sweden

Abstract

Summary

Despite numerous studies documenting the association between cancer and venous thromboembolism (VTE), the reason for the excessive risk in certain cancers remains obscure. No large-scale studies have yet investigated the independent effects of cancer type,site and growth pattern.Between 1970 and 1982, 23,796 standardised autopsies were performed, representing 84% of all in-hospital deaths in an urban Swedish population.The relationship between cancer and PE was evaluated with logistic regression.The overall PE prevalence was 23%, and 10% of the population had a fatal PE. Forty-two per cent of pancreatic cancer patients had PE (OR 2.55; 95% CI 2.10–3.09) (p<0.001); gall bladder, gastric, colorectal and pulmonary adenocarcinomas were similarly independently associated with PE. In comparison with squamous cell lung cancer, patients with pulmonary adenocarcinoma had 1.65 times higher odds for PE (95% CI 1.20–2.29). Adenocarcinoma and metastatic cancer were independently associated with PE risk (OR 1.27; 95% CI 1.16 – 1.40; p<0.001, and OR 1.10;95% CI 1.01 – 1.20; p=0.024, respectively) but when controlling for cancer type and spread, pancreatic cancer was still associated with an OR of 2.10 (95% CI 1.71–2.58) of PE (p<0.001).We conclude that the risk of PE in cancer patients depends not only on the cancer site and spread but also on the histological type.The excess independent risk in pancreatic cancer is intriguing and should warrant further research.

Keywords

Clinical / epidemiological studies - malignancy - pulmonary embolism

Volltext

Referenzen

References
1 Sproul EE. Carcinoma and venous thrombosis: the frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis. Am J Cancer 1938; 34: 566-85.
2 Thompson CM, Rodgers RL. Analysis of the autopsy records of 157 cases of carcinoma of the pancreas with particular reference to the incidence of thromboembolism. Am J Med Sci 1952; 223: 469-78.
3 Heit JA, Silverstein MD, Mohr DN. et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost 2001; 86: 452-63.
4 Rickles FR, Levine MN. Venous thromboembolism in malignancy and malignancy in venous thromboembolism. Haemostasis 1998; 28 (Suppl. 03) 43-9.
5 Gore JM, Appelbaum JS, Greene HL. et al. Occult cancer in patients with acute pulmonary embolism. Ann Int Med 1982; 96: 556-60.
6 Griffin MR, Stanson AW, Brown ML. et al. Deep venous thrombosis and pulmonary embolism. Risk of subsequent malignant neoplasms. Arch Int Med 1987; 147: 1907-11.
7 Monreal M, Lafoz E, Casals A. et al. Occult cancer in patients with deep venous thrombosis.A systematic approach. Cancer 1991; 67: 541-5.
8 Prandoni P, Lensing AW, Buller HR. et al. Deepvein thrombosis and the incidence of subsequent symptomatic cancer.[see comment]. N Engl J Med 1992; 327: 1128-33.
9 Bastounis EA, Karayiannakis AJ, Makri GG. et al. The incidence of occult cancer in patients with deep venous thrombosis:a prospective study. Journal of Internal Medicine 1996; 239 (02) 153-6.
10 Otten HM, Prins MH. Venous thromboembolism and occult malignancy: an historical perspective. Haemostasis 2001; 31 (Suppl. 01) 32-3.
11 Baron JA, Gridley G, Weiderpass E. et al. Venous thromboembolism and cancer.[erratum in Lancet 2000;355: 758]. Lancet 1998; 351: 1077-80.
12 Sorensen HT, Mellemkjaer L, Steffensen FH. et al. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism [see comment]. N Engl J Med 1998; 338: 1169-73.
13 Trousseau A. Phlegmasia alba dolens. In: Clinique Médicale de l’Hotel-Dieu de Paris. J-B Ballière et fils 1877; 695-739.
14 Falanga A. Mechanisms of hypercoagulation in malignancy and during chemotherapy. Haemostasis 1998; 28 (Suppl. 03) 50-60.
15 Rickles FR, Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res 2001; 102: V215-24.
16 Blom JW, Osanto S, Rosendaal FR. The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma. J Thromb Haemost 2004; 02: 1760-5.
17 Sternby NH. Atherosclerosis in a defined population. An autopsy survey in Malmo, Sweden. Acta Pathol Microbiol Scand 1968; Suppl 194: 5-216.
18 Bergqvist D, Lindblad B. A 30-year survey of pulmonary embolism verified at autopsy: an analysis of 1274 surgical patients. Br J Surg 1985; 72: 105-8.
19 Acosta S, Ogren M, Sternby NH. et al. Incidence of acute thrombo-embolic occlusion of the superior mesenteric artery--a population-based study. Eur J Vasc Endovasc Surg 2004; 27: 145-50.
20 Wahrenbrock M, Borsig L, Le D. et al. Selectinmucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J Clin Invest 2003; 112: 853-62.
21 Altinbas M, Coskun HS, Er O. et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004; 02: 1266-71.